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1. Introduction  
Because of their hydrophilic natures, movements of nucleosides and many of their 
analogues across cellular membranes are mediated by nucleoside transporter (NT) proteins. 
Thus, NT proteins play an important role in physiological actions of nucleosides and in 
alterations of their function under various pathophysiological conditions. Also, these 
proteins are important for the therapeutic actions of some of synthetic nucleosides that have 
pharmacological actions and are thus used as drugs, including nucleoside analogues reverse 
transcriptase inhibitors (King et al., 2006, Zhang et al., 2007).  
Before the “molecular biology” era, it was possible to explore nucleoside transport processes 
mainly by functional transport studies, which measured transcellular flux or cellular uptake 
of radiolabelled nucleosides. These early studies have identified two distinct transport 
processes in mammalian cells: the equilibrative bidirectional transport with lower affinity 
for naturally occurring nucleosides and the concentrative, unidirectional secondary active 
transport (Na+/nucleoside cotransport) which revealed higher affinity for nucleosides 
(Hyde et al., 2004, Baldwin et al., 2004). Also, based on inhibition of these processes by 
synthetic analogues and based on substrate specificity and kinetics, it was recognized that 
both groups were heterogeneous: equilibrative nucleoside transport processes were further 
categorized as either nitrobenzylthioinosine (NBMPR)-sensitive (es) or NBMPR-insensitive 
(ei), while  concentrative transport processes were categorized as either cit (concentrative, 
NBMPR insensitive, thymidine important substrate), cif (concentrative, NBMPR insensitive, 
formycin B important substrate) or cib (concentrative, NBMPR insensitive, broadly selective 
for purine and pyrimidine nucleosides) (Cass et al., 1998). Transport studies have also 
revealed that all these transport processes are not ubiquitously distributed in all mammalian 
cells; while equlibrative transport processes were more or less ubiquitous, concentrative 
transport processes were mainly found in epithelia, endothelial layers and in the liver (for 
an early review of nucleoside transport processes see Young and Jarvis 1983). 
Development of molecular biology techniques has allowed identification of the proteins 
responsible for nucleoside transport processes (King et al., 2006). Purification and N-terminal 
sequencing of the es transporter from human erythrocytes enabled cloning a human placental 
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cDNA encoding the corresponding transporter in 1996 (Griffiths et al., 1997a). cDNA clones 
encoding one of the ei-type transporter were subsequently  isolated (Griffiths et al., 1997b, 
Crawford et al., 1998), while the remaining two ei-type transporters were identified and 
isolated as a result of the completion of the human genome project (Hyde et al., 2001). The 
isoforms corresponding to pyrimidine-, purine- and broadly selective concentrative nucleoside 
transport have been cloned and their structure was defined (Che et al., 1995, Ritzel et al., 1997, 
Wang et al., 1997, Gerstin et al., 2000, Patel et al., 2000, Ritzel et al., 2001).  
All these proteins are members of two structurally unrelated protein families that are named 
(according to processes that they mediate) as equilibrative nucleoside transporter family 
(ENT) and concentrative nucleoside transporter family (CNT). These two familes are 
members of a superfamily of solute carriers (SLC), which includes facilitated transporters, 
ion-coupled transporters and exchangers that do not require ATP; ENT-family and CNT-
family are in humans known as SLC29 and SLC28, respectively.  
2. Molecular biology of nucleoside transporters  
So far, seven nucleoside transporter proteins were identified and described in mammals; 
four of them belong to the ENT family and are categorized as ENT1-4, while three of them 
belong to the CNT family and are categorized as CNT1-3. 
2.1 Equilibrative nucleoside transporter family  
 
 
Fig. 1. Structures of naturally occurring nucleosides and nucleobases and their transport by 
human NT families. Reproduced with permission from Parkinson et al. (2011b).   
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Equilibrative nucleoside transporters are present in many cell types and they transport a 
broad range of purine and pyrimidine nucleosides (Griffits et al., 1997a, Griffits et al., 
1997b); hENT2 also transports nucleobases (Figure 1) (Yao et al., 2002). hENT3 functions 
predominantly in intracellular membranes (Baldwin et al., 2005), while hENT4 is also 
known as plasma monoamino transporter and transport monoamines in the brain and heart, 
while it transports adenosine only at low pH  (Barnes et al., 2006, Zhou et al., 2007). 
2.1.1 Inhibition by synthetic analogues of nucleosides  
As it was mentioned above, early transport studies have recognized that nucleoside 
analogue NBMPR, when present in nanomolar concentrations, inhibited partially 
equilibrative transport. It is known today that this molecule is highly specific inhibitor of 
nucleoside transport via ENT1 protein, which mediates es-type transport activity. Because 
hENT1 is inhibited by nanomolar NBMPR, whereas hENT2, hENT3 and hENT4 are either 
unaffected by NBMPR or inhibited by micromolar concentrations, this synthetic analogue 
was extensively used for studies of ENT1 protein.  
Both ENT1 and ENT2 are also inhibited by drugs such as dipyridamole and dilazep, which 
are also used as coronary vasodilators because by blocking equilibrative uptake of 
adenosine they increase extracellular concentration of this nucleoside, thereby producing 
vasodilation; dilazep, dipirydamole and NBMPR bind either to or adjacent to the outward-
facing region of the permeant-binding site (Baldwin et al., 2004). NBMPR and dipyridamole 
inhibit hENT1 with Ki values of <5 and 20 nM, respectively, and hENT2 with Ki values of 
>1 and 150 μM, respectively (Griffits et al., 1997a, Visser et al., 2002). 
NBMPR is a membrane permeable nucleoside analogue; thus, if [3H]NBMPR is used in a 
study, it will label all extracellular and intracellular binding sites, which makes relative 
quantification of extra- or intracellular binding sites impossible. To overcome this problem, 
a membrane-impermeant ENT1 ligand  5'-S-{2-(1-[(fluorescein-5-yl)thioureido]-
hexanamido)ethyl}-6-N-(4-nitrobenzyl)-5'-thioadenosine (FTH-SAENTA) was developed 
(Visser et al., 2007). This ligand was used for competitive binding studies with a logic 
behind its application that in the absence of FTH-SAENTA, [3H]NBMPR will bind for all 
binding sites (intracellularly and extracellularly), while in the presence of FTH-SAENTA, 
only intracellular binding sites will be labeled. This approach enabled differentiation of 
intra- and extracellular [3H]NBMPR binding sites and revealed that the intracellular 
distribution of hENT1 varies largely in different cell types (Paproski et al., 2008), and was 
mainly confined to nuclear membranes (Mani et al., 1998) and mitochondria (Lee et al., 
2006). hENT1 also undergoes intensive trafficking and recycling (see below) which could be 
another explanation for relatively high proportion of [3H]NBMPR binding sites present 
intracellualrly. 
2.2 Molecular properties, expression and mechanism of transport of ENTs  
Four ENT proteins have been encoded in the human , rat and mouse genomes and the 
abbreviations used for those proteins are hENTs, rENTs and mENTs, respectively (Griffits 
et al., 1997a, Griffits et al., 1997b, Baldwin et al., 2005, Barnes et al., 2006). They have been 
also produced as recombinant proteins in African clawed frog (Xenopus laevis) oocytes, 
that allowed detailed kinetic studies of transport processes; data obtained mainly by this 
technique, which describe kinetics of transport of naturally occurring nucleosides and  
nucleobases towards hENTs are presented in Table 1, while kinetic of transport of 
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synthetic analogues that are used as reverse transcriptase inhibitors drugs by hENTs are 
presented in Table 2.  
 
Molecule 
Nucleoside 
transporter that 
mediate transport
Available Km values (mM) 
(transporter is indicated in 
brackets) 
Source 
Nucleosides    
Adenosine  
hENT1-4 & 
hCNT1-3 
0.8 (hENT4), 0.008 
(hCNT2), 0.015 (hCNT3) 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Barnes 
et al., 2006; Ritzel et al., 1997; 
2001; Smith et al., 2004  
Guanosine 
hENT1-3, hCNT2, 
hCNT3 
0.04 (hCNT3) 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Ritzel et 
al., 1997; 2001 
Inosine 
hENT1-3, hCNT1, 
hCNT3 
0.005 (hCNT1), 0.05 
(hCNT3) 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Ritzel et 
al., 1997; 2001 
Uridine 
hENT1-3, hCNT1-
3 
0.24 (hENT1), 0.2 (hENT2), 
2.0 (hENT3), 0.03 (hCNT1),
0.04 (hCNT2), 0.015 
(hCNT3)* 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Ritzel et 
al., 1997; 200; Slugoski et al., 
2007, 2008;  
Cytidine 
hENT1-3, hCNT1, 
hCNT3 
0.02 (hCNT1), 0.015 
(hCNT3) 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Ritzel et 
al., 1997; 200; Slugoski et al., 
2007, 2008;  
Thymidine 
hENT1-3, hCNT1, 
hCNT3 
0.03 (hCNT1), 0.02 
(hCNT3) 
Griffits et al., 1997a; 1997b; 
Baldwin et al., 2005; Ritzel et 
al., 1997; 200; Slugoski et al., 
2007, 2008;  
Nucleobases    
Hypoxanthine hENT2 0.7 Yao et al., 2002 
Adenine hENT3, hENT3 1.1 (hENT2) 
Yao et al., 2002; Baldwin et 
al., 2005,  
Thymine hENT2 1.7 Yao et al., 2002 
Uracil  hENT2 2.6 Yao et al., 2002 
Table 1. Selectivity of human nucleoside transporters (expressed in Xenopus oocytes) for 
naturally occurring nucleosides and nucleobases. Affinity of ligands for transporters is also 
presented as Michaelis constant Km. * This value is for Na+ containing medium; in H+ 
containing medium Km is 0.06. 
As mentioned above, the main location of ENT1 and ENT2 is the plasma membrane. 
However, immuno-staining and [3H]NBMPR  binding studies have often revealed a diffuse 
staining of cells. In example, when mouse CP was stained with these antibodies, obtained 
images revealed diffuse staining of CP epithelial cells in the case of mENT1 and disuse 
staining with a weak membrane staining of mENT2 (Parkinson et al., 2011).  Such findings 
reflect, at least partially, abundant recycling and intracellular trafficking of those proteins. 
Studies that assessed NBMPR-binding in chromaffin cells suggested that NBMPR-binding 
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disappears from the plasma membrane in about 5 hours, suggesting that ENT1 was 
internalized, with about 50% of this protein is recycled to the plasma membrane and the 
remaining protein probably degraded  (Torres et al., 1992). A recent study has provided an 
important insight into the life cycle of human equilibrative nucleoside transporters (Nivillac 
et al., 2011). In this study, green fluorescence protein-tagged or FLAG- tagged hENT1 was 
transiently transfected into mammalian cells and the sequence of events regulating the 
hENT1 life cycle was studied; protein translocation to the plasma membrane was examined 
using fixed and live cell confocal microscopy (Nivillac et al., 2011). This study revealed that 
that the entire life cycle of the tagged-hENT1 protein was approximately 14 hours following 
translation, folding and ER export (Nivillac et al., 2011). After exiting the ER, hENT1 was 
translocated to the Golgi and glycosylated. Glycosylation probably plays a significant role in 
trafficking and function for a number of transporters including ENTs (Cai et al., 2005, 
Hendriks et al., 2004, Tanaka et al., 2004). hENT1 was then trafficked to the plasma 
membrane in association with the microtubule network in a variety of vesicles; in the 
plasma membrane hENT1 was co-localized with actin, which suggested that this transporter 
was anchored in the membrane by the actin cytoskeleton (Nivillac et al., 2011). This finding 
was consistent with previous observations for some other transporters, such as mouse 
GABA transporter 1 (Moss et al., 2009). After about an hour at the plasma membrane hENT1 
internalized and interestingly only a proportion of the transporter population was recycled, 
which could indicate an efficient mechanism for fine-tuning, similar to what was described 
for  the organic anion exchanger OAT1 (Zhang et al., 2008). Finally, internalized protein is 
degraded via the lysosomal pathway and observations suggest the complete life cycle of 
tagged hENT1 within these cells is approximately 14 hours. 
In addition to studies on ENT 1 trafficking, efforts were also made to understand the 
mechanisms by which expression of ENT1 is modulated. A study investigated whether 
stress-activated kinases regulate ENT1 expression and function, using a mouse myeloid 
leukemic cell line as a model. It was revealed that  Jun N-terminal kinase activation resulted 
in rapid loss of mENT1 function, mRNA expression and promoter activity; c-Jun decreased 
mENT1 promoter activity, which suggested a specific role for this transcription factor in 
mENT1 regulation. Overall, this study concluded that activation of JNK-cJun pathway 
negatively regulates mENT1(Leisewitz et al., 2011). 
Current knowledge suggest that ENT3 is present in most tissues, including brain (Lu et al., 
2004). It was  found to co-localize with lysosomal markers and showed broad selectivity and 
low affinity towards the naturally occurring nucleosides and was unaffected by micromolar 
NBMPR, dipyridamole or dilazep (Baldwin et al., 2005). It was also indicated that hENT3 
was found in mitochondrial membrane in several human cell lines (Govindarajan et al., 
2009). Human and mouse ENT3 have a long hydrophilic N-terminus that contains a 
conserved characteristic of endosomal and /or lysosomal targeting sequences (Baldwin et 
al., 2005). Thus, when expressed in Xenopus oocytes, hENT3 and mENT3 did not have 
functional role in transport across the plasma membrane unless the N-terminus was 
modified (Baldwin et al., 2005). This transporter is activated at low pH (proton-dependent 
activation), which may be an important feature for its localization in acidic environment, 
like lysosomes and mitochondria. A physiological function of this transporter could be to 
transport nucleosides and nucleobases that are produced by nucleic acid breakdown in 
lysosomes and to provide material for mitochondrial DNA synthesis. A recent study 
revealed that hENT3 mRNA was the most abundant when compared to other hNTs mRNAs 
in human choroid plexus (Redzic et al., 2010). 
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Immunocytochemistry and immunonlotting have detected presence of ENT4 in human and 
mouse brain and in human, mouse and rat heart (Barnes et al., 2006). hENT4 revealed 
selectivity for adenosine, while mENT4 also shows affinity to transport adenine; affinity for 
substrates appears to be low and proton-dependent  (Barnes et al., 2006). hENT4 is 
unaffected by as much as 1 μM NBMPR and only partially inhibited by micromolar 
dipyridamole. This transporter is also known as plasma membrane monoamine transporter 
(PMAT); experimental data also suggest that transport of substrates by h/mENT4 is 
inhibited by organic cation transporter inhibitor 1,1'-diethyl-2,2'-cyanine (decynium-22) and 
dopamine transporter inhibitor (Barnes et al., 2006). Structure analysis suggested that 
human and mouse ENT4 are closely related to ENT3 in a fruit fly (Drosophila melanogaster), 
rather than to human and mouse ENT1, a data that could suggest early divergence from 
other mammalian ENTs during the evolution (Barnes et al., 2006).  
2.3 Molecular properties of transport by concentrative nucleoside transporters  
CNT1 and CNT2 proteins are found primarily in epithelial tissues of small and large 
intestine, kidney, liver, heart  (CNT2), pancreas (CNT2), skeletal muscle (CNT2), brain 
endothelial cells (CNT2)  and choroid plexus (CNT2) (Gray et al., 2004, Redzic et al, 2005). 
CNT3 protein is found the pancreas, trachea, bone marrow, mammary gland and choroid 
plexus (Gray et al, 2004, Redzic et al., 2005, Redzic et al., 2010). Structure of human, rat and 
mouse CNTs is largely identical, with hCNT1 and rCNT1 being 83% identical at protein 
level, hCNT2 and rCNT2 being 81% identical and hCNT3 and mCNT3 being 78% identical 
(Gray et al., 2004). CNT1 is pyrimidine selective, but also transports adenosine with high-
affinity and low capacity (Ritzel et al., 2001); CNT2 transport purine nucleosides and 
pyrimidine uridine (Wang et al., 1997, Ritzel et al., 1998), while CNT3 is broadly selective 
and transports both purine and pyrimidine nucleosides (Ritzel et al., 1997).  
Membrane transport of nucleosides by CNTs takes place in symport with Na+ and/or H+. 
Thus, this process is electrogenic, since an uncharged particle (i.e. nucleoside) is transported 
together with an ion. If these transporters are produced as functional recombinant proteins 
in a heterologous expression system (i.e. Xenopus oocytes), molecular properties of 
nucleoside transport could be studied by steady-state electrophysiology techniques, using 
the two microelectrode voltage-clamp (Smith et al., 2005).  
Using this approach, it has been shown that hCNT1 and hCNT2 are coupling nucleoside 
translocation to cotransport of Na+ (i.e. they are Na+-specific) (Smith et al., 2004), while 
hCNT3 couples nucleoside translocation to cotransport of Na+ and H+ (Smith et al., 2005). 
For hCNT1 and hCNT2 the coupling ratio is 1:1, while for hCNT3 the Na+:nucleoside 
coupling ration is 2:1, while the H+:nucleoside coupling ratio is 1:1 (Smith et al., 2007). 
Pre-steady-state currents measurements in hCNT-producing Xenopus oocytes revealed the 
transporter valence to be -1 and -2 for hCNT1 and hCNT3, respectively; it was estimated 
that 1010 to 1011 hCNT2 and hCNT3 transporters were present per oocyte (Smith et al., 2004, 
2005). The sequence of events during CNTs-mediated transport has been elucidated 
partially. First Na+ and/or H+ bind to hCNT1 or hCNT3 and this event increases the affinity 
of these proteins for nucleoside substrates; in the case of hCNT3, after nucleoside binding it 
binds second Na+ (Smith et al., 2004, 2005). Thus, the Na+ coupling ratio for hCNT3 (2:1) if 
compared to the Na+ coupling ratio for hCNT1 (1:1) suggests that the former one is more 
capable to transport nucleosides against their concentration gradient. Interestingly, H+ 
binding for hCNT3 changes its conformation (when compared hCNT3 with Na+ ion bound), 
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so  Na+-coupled hCNT3 transports purine and pyrimidine nucleosides and also nucleoside 
analogue reverse transport inhibitor zidovudine,  while H+-coupled hCNT3 is selective for 
pyrimidines and does not transport zidovudine (Smith et al, 2005).   
3. Distribution of nucleoside transporters in the brain 
Expression of nucleoside transporters in the brain was mainly explored by techniques in situ 
(i.e. ligand binding and immunostaining of brain slices or various brain regions), 
immunoblotting and by in vitro techniques (i.e. cell cultures). Surprisingly, those approaches 
often produced  conflicting results. In example, an in situ study that used polyclonal 
antibodies against rENT1 and rENT2 revealed that those transporters were present in all 
neurons explored, while only some astrocytes showed rENT1 staining, while rENT2 staining 
on astrocytes was observed only sporadically (Alanko et al., 2006) Contrary to this finding, a 
study that used immunoblotting on rat astrocytes in primary culture has clearly revealed 
that both rENT1 and rENT2 were present (Redzic et al., 2010b). Those discrepancies could 
be partially explained by dedifferentiation of cells in culture.  
3.1 Equilibrative nucleoside transporter 1 
ENT1 was by far the most well studied nucleoside transporter in the brain. This was largely 
because a specific ligand NBMPR that binds to this protein with high affinity was available 
(see above). Thus, most of our current knowledge was gained on studies that used brain 
sections that were incubated with [3H]NBMPR, with unlabelled NMBPR being used to 
define non-specific binding and with autoradiography film being used to visualize the 
distribution of specific binding sites. These studies have revealed localized distribution of 
binding sites for this radioligand, indicating uneven distribution of ENT1 in rodent brain, 
which was unexpected because a general view was that ENT1 is an ubiquitous nucleoside 
transporter. High [3H]NBMPR binding was detected in thalamus and superior colliculus, 
while low binding was detected in hippocampus, cerebral cortex and cerebellum; other 
regions show no ligand binding (Geiger et al., 1984, Parkinson et al., 1996, Bailey et al., 
2002). Contrary to this, immunocytochemistry studies has revealed more even distribution 
of this transporter throughout the brain, with a strong signal being detected in cerebral 
cortex, hippocampus, striatum and cerebellum (Alanko et al., 2006). 
In situ hybridization studies that detected distribution of mRNA encoding ENT1 have 
revealed its wide distribution in the brain with a strong signal being detected from 
hippocampus, cerebellum, cerebral cortex and striatum (Anderson et al., 1999). This 
technique has also detected ENT1 mRNA in astrocytes, and choroid plexus epithelial cells.  
Distribution of hENT1 in human brain has also been investigated and these studies have 
revealed that hENT1 mRNA was very abundant in caudate nucleus, amygdale, 
hippocampus and thalamus, while it was scarce in substantia nigra; like in the rodent brain, 
there was no correlation between those findings and hENT1 protein distribution, which was 
greatest in several areas of cerebral cortex, much lower in thalamus and basal ganglia, and 
scarce in hippocampus and cerebellum (Jennings et al, 2001). However, in the human brain, 
a positive correlation was shown between hENT1 distribution and adenosine A1 receptors 
distribution (Jennings et al, 2001), which was opposite to findings in the rodent brain, where 
a correlation between rENT1 and A1 receptors distribution was either poor (Geiger et al., 
1984, Bailey et al., 2002) or negative (Parkinson et al., 1996).  
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3.2 Equilibrative nucleoside transporter 2  
Since there is no high-affinity ligand for ENT2 available so far, studies that explored 
distribution of ENT2 in the brain employed a strategy in which brain slices were probed 
with radiolabelled dipyridamole, a ligand that binds more or less equally to ENT1 and 
ENT2 and with radiolabelled dipyridamole in the presence of unlabelled NBMPR, which in 
nanomolar concentration binds to ENT1 (and thus block dipyridamole binding for this 
transporter). Under those circumstances, the detected radiligand binding that was not 
blocked by the presence of nanomolar NBMPR but was blocked by micromolar NBMPR 
could be largely attributed to ENT2. A problem with this strategy is that dipyridamole is 
very lipophilic and thus binds unspecifically, which limits  usefulness of data drawn from 
these studies. Data available so far suggest that for guinea pig CNS membranes 40-50% of 
[3H]dipyridamole binding could be attributed to ENT2 (Jones and Hammond, 1992). 
Some studies have measured uptake of [3H] adenosine in the presence of nanomolar 
NBMPR and in the presence of dipyridamole. The logic behind these studies was that 
adenosine cellular uptake via rENT1 would be inhibited by the presence of nanomolar 
NBMPR, while adenosine upake via both transporters would be inhibited in the presence of 
dipyridamole, so a difference between uptake rates under those two conditions could be 
credited to uptake via rENT2. Using this strategy it was revealed that [3H] adenosine uptake 
by primary cultures of rat cerebral neurons and astrocytes was inhibited by >20 and >30% 
by the presence of nanomolar NBMPR, respectively, while dipyridamole inhibited more 
than 80% of uptake, which indicated that rENT2 was functionally more abundant than 
rENT1 in these cells (Parkinson et al., 2005).  
Immunocytochemistry revealed that rENT2 had a widespread distribution of in rat brain 
and that this distribution largely overlapped with distribution of rENT1 (Alanko et al., 
2006). Distribution of rENT2 mRNA in rat brain was widespread and more abundant than 
distribution of rENT1 and mRNA was localized in cerebral cortex, striatum, thalamus, 
hippocampus and cerebellum, choroid plexus and blood vessels (Anderson et al., 1999). 
Primary cultures of rat neurons and astrocytes also had more abundant mRNA for rENT2 
than for rENT1, as revealed by quantitative RT-PCR  (Parkinson et al., 2006). 
3.3 Other equilibrative nucleoside transporters  
It was revealed that rat and mouse brain express mRNA for ENT3 [Baldwin et al., 2005, 
Parkison et al., 2006). Human choroid plexus expressed abundantly hENT3 mRNA 
(Redzic et al., 2010a). However, so far there are no data demonstrating functional role of 
this transporter in the brain. Human, mouse and rat brain also express ENT4 mRNA 
that was widespread in neurons [Barnes et al., 2006, Parkinson et al., 2006, Vialou et al., 
2007). Immunocytochemistry did not reveal presence of this transporter in astrocytes 
(Dahlin et al., 2007). 
3.4 Concentrative nucleoside transporter 1 
Amount of CNT1 mRNA in the brain was less abundant than in epithelia (Lu et al., 
2004). In the brain, CNT1 mRNA was detected by in  cerebral cortex, hypothalamus, 
hippocampus, cerebellum and choroid plexus (Lu et al., 2004). Rat astrocytes in primary 
culture express rCNT1 transcript, as revealed by RT-PCR, but the abundance was very 
low; however, rCNT1 protein was detected in these cells by immunoblotting (Redzic et 
al. 2010b). 
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3.5 Concentrative nucleoside transporter 2 
The relative abundance of CNT2 mRNA in the rodent brain was low when compared to 
epithelial, barrier-forming layers, like intestine (Lu et al., 2004). RT-PCR revealed that 
distribution of rENT2 mRNA was widespread and uniform in all rat brain regions examined 
(Anderson et al., 1996). In situ hybridization revealed that neurons in the hippocampus, 
basal ganglia, cerebral cortex, hypothalamus and cerebellum had intense signal (Guillen-
Gomez  et al., 2004). Interestingly, in situ studies showed that CNT2 mRNA was not present 
in astrocytes (Guillen-Gomez  et al., 2004), but it was present in primary cultures of mouse 
and rat astrocytes and functional activity of this transporter in those cells was revealed 
(Nagai et al., 2005, Peng et al., 2005, Redzic et al., 2010b). However, rCNT2 protein was 
absent from rat astrocytes in primary culture (Redzic et al., 2010b). 
3.6 Concentrative nucleoside transporter 3 
Rat and mouse brain revealed low abundance of CNT3 mRNA (Lu et al., 2004). mRNA was not 
detectable in primary cultures of rat neurons and astrocytes (Nagai et al., 2005, Redzic et al., 
2010b), but surprisingly rCNT3 protein was detected in cultured rat astrocytes (Redzic et al., 
2010b). Human brain contained hCNT3 transcripts, but with low abundance (Ritzel et al., 2001).  
3.7 Expression of nucleoside transporters in the brain of ENT1-knockout mice 
Genetic variation of equilibrative nucleoside transporters are very rare, which indicated that 
function of those proteins could be essential for the survival; thus, efforts were made to 
produce ENT1-knockout mouse, in order to analyze effects of mENT1 absence on homeostasis 
and on expression of other nucleoside transporters (for the procedure Choi et al., 2004). 
Surprisingly, it was found that mice lacking mENT1 have similar pattern of distribution of 
other nucleoside transporters as wild-type mice. A study that examined if the ENT1-null 
mouse heart was cardioprotected in response to ischemia  showed that ENT1-null mouse 
hearts showed significantly less myocardial infarction (after 30-min coronary occlusion) 
compared with wild-type littermates (Rose et al., 2010). Wild-type adult mouse 
cardiomyocytes express predominantly ENT1 and this transporter was primarily responsible 
for purine nucleoside uptake; thus, ENT1-null cardiomyocytes exhibit severely impaired 
nucleoside transport that could cause a higher increase in extracellular adenosine following 
ischemia than in wild-type mouse (Rose et al., 2010). However, adenosine receptor expression 
profiles and expression pattern of ENT2, ENT3, and ENT4 were similar in cardiomyocytes 
isolated from ENT1-null adult mice compared with cardiomyocytes isolated from wild-type 
littermates (Rose et al., 2010). Quantitative RT-PCR was used to investigate mENT1-4 and 
mCNT1-3 transcripts in wild-type and ENT1-null mouse brain (Parkinson et al., 2011). This 
study  showed that the most abundant transporter in wild-type brain was mENT1, while 
mENT2 was most abundant in the mENT1-null brain (Parkinson et al., 2011). Beside this 
difference, the NT expression patterns were similar between the wildtype and mENT1-null 
whole brain. This indicated that absence of mENT1 could be at least partially compensated by 
increased expression of mENT2 (Parkinson et al., 2011). 
4. Nucleoside transporters at the blood-brain barrier and at the blood-
cerebrospinal fluid barrier 
A constant and well-controlled composition of the extracellular fluid in the central nervous 
system (CNS) is essential for efficient neuronal processing. To control the brain 
microenvironment, the endothelial blood-brain barriers (BBB) exists in all vertebrates, except 
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for a few fish species (Bundgaard and Abbott, 2008). The BBB and the blood-cerebrospinal 
fluid barrier (BCSFB) are formed by brain endothelial cells (BECs) and choroid plexus (CP) 
epithelial cells, respectively (for a review see Redzic, 2011). The BBB and the BCSFB are not 
only anatomical barriers, but also dynamic tissues that express multiple transporters, 
receptors and enzymes.  
 
 
Fig. 2. A proposed distribution of rENTs and rCNTs in rat brain endothelial cells (A) and in 
rat choroid plexus epithelial cells (B). A model was proposed based on in vitro data, when 
rat brain endothelial cells and rat choroid plexus epithelial cells were grown as monolayers 
on permeable supports (Redzic et al., 2005, Redzic et al., 2006). 
The two main functions of these barriers are to impede free diffusion between brain fluids 
and blood and to provide transport processes for essential nutrients, ions and metabolic 
waste products. Presence of tight junctions between adjacent brain endothelial cells or 
choroid plexus epithelial cells restrict paracellular diffusion across these cellular layers. 
Thus, hydrophilic molecules (like naturally occurring nucleosides) cannot readily enter 
brain ISF or CSF by simple diffusion and must be transferred across the layer by ENTs and 
CNTs located in these cellular layers. On the other hand, many synthetic nucleosides and 
some nucleobases are scarcely soluble in water and they are more soluble in lipids; such 
molecules can diffuse into lipid bilayers, but both the BBB and the BCSFB use ATP-driven 
transporters that mediate efflux of lipophilic molecules (Miller, 2010). 
Adenosine transport across the BBB was investigated in vivo; efflux transport studies (brain 
intracellular fluid (ISF) to blood transport) and influx transport studies (blood to brain ISF 
transport) were performed following intracerebral and intracarotid injections of 
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[14C]adenosine, respectively,  together with a [3H]vascular space marker (Isakovic et al., 
2004). This study revealed that estimated BBB efflux clearance of [14C] radioactivity after 
intracerebral injection of [14C]adenosine was almost threefold higher than the estimated BBB 
influx clearance of radioactivity after intracarotid injection of this molecule (Isakovic et al., 
2004). However, if the values of Vmax and Km calculated from this study plus the reported 
brain ISF adenosine concentration (Melani et al. 1999) are inserted into the Michaelis 
equation, an estimated velocity of BBB efflux transport in vivo was 100-fold lower than the 
reported rate of uptake of adenosine into neurones/glia (Lawrence et al. 1994) and the rate 
of phosphorylation by adenosine kinase inside the cells (Phillips and Newsholme 1979), 
which indicates that adenosine BBB efflux transport does not play an important role in 
adenosine homeostasis under resting physiological conditions. This study also revealed that 
most [14C]radioactivity in plasma appeared with the HPLC peaks for adenosine metabolites 
adenine and hypoxanthine after the intracerebral injection of [14C] adenosine, while 
negligible amounts appeared within the adenosine peak; this suggested that the brain 
capillary endothelial cells appear to act as an enzymatic barrier for adenosine, rapidly 
degrading this molecule (Isakovic et al., 2004). Using the same technique, the BBB efflux 
transport of other purines was studied in vivo after the intracerebral injection of 
radiolabelled purines; this study has revealed rapid BBB efflux clearance of hypoxanthine 
and adenine (Isakovic et al., 2002).   
Rat brain endothelial cells (RBECs) were also grown as primary monocultures on permeable 
supports (filters); under those circumstances they developed transcellular electrical 
resistance that was sufficient to provide separate studies of cellular uptake with upper 
chamber as a donor and with lower chamber as a donor (Redzic et al., 2005). This study 
revealed that  RBECs expressed rENT1, rENT2 and rCNT2 mRNA and protein;  
interestingly, rCNT2 was the most abundant at both transcript and protein level. Transcripts 
for rCNT1 and rCNT3 were either absent or of very low abundance. [3H]adenosine transport 
data revealed that the cellular uptake of this nucleoside was sodium-dependent only when 
lower chamber was a donor. Sodium-independent uptake of adenosine was observed across 
both membranes, consistent with detection of both rENT1 and rENT2 proteins in these cells, 
but the pattern of inhibition by NBMPR  suggested that rENT1 was confined to the 
membranes facing the upper chamber, whereas rENT2 was probably present in both 
membrane domains (Redzic et al., 2005). When RBEC are grown on permeable supports, the 
cellular membranes facing the lower and upper chambers display some of the characteristics 
of the in vivo basolateral (brain ISF-facing) and apical (blood-facing) membranes, 
respectively (Reichel et al. 2003). Therefore, findings from this study suggested that 
concentrative adenosine uptake at the BBB in vivo may be limited to the brain ISF-facing 
membrane, whereas transport via ENT1 occurs only on the opposite side. Such a pattern of 
nucleoside transporter distribution (presented in Figure 2A) combined with the detected 
rapid metabolism of adenosine in endothelial cells (Isakovic et al. 2004) may suggest that the 
role of the BBB is to remove adenosine from the brain ISF, rather than to mediate uptake of 
this purine nucleoside from the circulation. 
Primary cultures of sheep CP epithelial cells (CPEC) were also grown as monolayers on 
permeable supports (Redzic et al., 2006) and these cells expressed some features typical of the 
CPEC in situ; they developed relatively high transepithelial electrical resistance which was 
accompanied by low  paracellular permeability, a property that enabled the use of this model 
for studies of transcellular transport of radiolabelled adenosine. Transcellular permeability of 
these monolayers towards [14C]adenosine was surprisingly low, but when adenosine 
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intracellular metabolism was inhibited, there was more than a five-fold increase in the 
transcellular permeability for [14C]adenosine, which indicated that intracellular 
phosphorylation of adenosine into nucleotides and/or its degradation into nucleobases that 
show different kinetic properties to adenosine might be the cause of low transcellular 
permeability. This study also applied HPLC analysis with simultaneous detection of 
radioactivity and revealed that [14C] radioactivity which appeared in the acceptor chamber 
after the incubation of CPEC monolayers with [14C]adenosine in the donor chamber, mostly 
was present as [14C] hypoxanthine, which indicated that sheep CPEC in primary culture, 
similarly to the rat brain endothelial cells, act as an enzymatic barrier towards adenosine 
(Redzic et al., 2006). Uptake studies on this model revealed that [14C]adenosine concentrative 
uptake was confined to the apical ('CSF') side of these cells, indicating uneven distribution of 
nucleoside transporters and a possible role in removing adenosine from the CSF.  
A study on sheep CPEC in primary culture, grown on permeable supports, gave an insight 
on nucleobase transport and metabolism in the CPEC; it was revealed that uptake of 
[14C]hypoxanthine by the apical side was partially Na+-dependent and partially Na+-
independent, the latter process being partially mediated by ENT2. Hypoxanthine was 
metabolized inside the CPEC through the action of hypoxanthine-guanine phosphoribosyl 
transferase, producing nucleotides and the nucleoside inosine. Some  hypoxanthine and 
inosine left CPEC through the opposite side of the cell. This might suggest that the uptake of 
hypoxanthine by the apical side of the sheep CPEC could serve two important functions in 
vivo, which was to provide material for local demands of the CPE for nucleotides through 
the salvage pathways, as well as to remove excess hypoxanthine to the CP interstitial fluid. 
The same model was also used to grow primary cultures of rat CPEC; RT-PCR and Western blots 
of revealed the presence of rENT1, rENT2, rCNT2 and rCNT3, but not the pyrimidine-preferring 
rCNT1 (Redzic et al., 2005). Adenosine uptake by these cells showed a polarized distribution of 
Na+-dependent transport of [14C]adenosine at the apical cell surface that could be attributed to 
rCNT2 and/or rCNT3. Na+-independent transport that was partially NBMPR-sensitive at the 
basolateral cell surface which could be attributed to the presence of rENT1 and rENT2 [91]. The 
remaining adenosine uptake at apical cell surfaces that was sodium-independent was NBMPR-
insensitive, thus could be attributed to rENT2 (Figure 2B) (Redzic et al., 2005).  
Expression of nucleoside transporters at transcript level and nucleoside uptake was studied 
in isolated portions of human lateral ventricle choroid plexuses that were obtained during 
neurosurgery (Redzic et al., 2010a). Quantitative RT-PCR  revealed  that transcripts for 
hENT1-3 and hCNT3 were present with mRNA for hENT3 being the most abundant. 
hCNT1 and hCNT2 transcripts were absent or present at very low abundance. Human CP 
samples took up radiolabelled inosine by both concentrative and equilibrative processes. 
However, the equilibrative uptake was mediated only by hENT2, while hENT1 transport 
activity was absent, which could suggested either that this protein was absent in the human 
CP or that it was confined to the basolateral side of the CP epithelium (which did not come 
in contact with uptake buffer in this study) (Redzic et al., 2010a). 
Thus, several lines of evidences suggest that polarized distribution of nucleoside transporters 
at the BBB and in the CP epithelium, with CNTs located on sides facing brain extracellular 
fluids (ISF and CSF) and equlibrative transport across the opposite, blood facing side, may 
play an important role in the removal of nucleosides from brain fluids. Also, it appears that 
brain endothelial cells represent an enzymatic barrier towards at least some nucleosides and 
nucleobases; this enzymatic activity may further impede blood to brain transport.  
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5. Expression of NTs in neurons and astrocytes and the role of these 
transporters in nucleoside homeostasis in the brain 
Adenosine concentration in the brain extracellular fluid (ECF) depends on three processes: 
(a) its formation in neurons (Zamzow et al., 2008, Parkinson et al. 2005) and transport from 
neurons across the plasma membrane to the ECF; (b) its formation extracellularly through 
the action of soluble or membrane bound ecto-nucleotidases on ATP that is released from 
astrocytes (Parkinson and Xiong, 2004) and uptake by astrocytes, a process that is  normally 
followed by intracellular conversion to inosine and hypoxanthine (Zamzow et al., 2008). 
However, relative contributions of intracellular and extracellular formation are not clear. A 
classical view suggests that adenosine is mainly formed intracellularly as a consequence of 
ATP hydrolysis; cellular concentrations of ATP are manifolds higher than concentrations of 
adenosine (Fredholm et al., 2005), so a small increases in ATP degradation can cause a large 
increase in adenosine concentration. Once it is formed, intracellular adenosine leaves cells 
by facilitated diffusion via ENTs. There are several lines of evidences showing that neurons 
in primary culture, after being exposed to hypoxia / glucose deprivation released adenosine 
and inosine (Parkinson et al., 2005, Parkinson and Xiong, 2004) and also release these two 
nucleosides when they were treated with the glutamate receptor agonist N-methyl-D-
aspartate (Zamzow et al., 2008, 2009), while dipyridamole, a non-selective ENT1/2 inhibitor 
in rat cells, inhibited this release.  
A non-classical view suggests that adenosine  is mainly formed extracellularly by a series of 
reactions catalyzed by ecto-nucleotidases following cellular release of ATP (Dunwiddie and 
Masino 2001). Evidences suggest that rat cortical astrocytes in primary cultures, when exposed 
to hypoxia, release adenosine and inosine, but that release was not blocked by dipyridamole, 
suggesting that transport across the plasma membrane did not play a role in this release 
(Parkinson and Xiong, 2004). Thus, it appears that in the brain both pathways for adenosine 
production are present, with neurons releasing mainly adenosine (as a product of ATP 
hydrolysis) and astrocytes releasing ATP that is hydrolysed extracellularly to adenosine 
(Parkinson et al., 2005). Furthermore, data suggest that adenosine that was produced by 
neurons was mainly taken up by astrocytes and metabolized intracellularly to hypoxanthine 
(Zamzow et al., 2008); hypoxanthine was then released in the ISF. The net effect of this process 
is that adenosine neuromodulatory action was time-limited, since adenosine was rapidly 
converted to nucleobase hypoxanthine, which has no effect in cell signaling.  
A study that explored the role of neuronal equilibrative NTs in adenosine influx and efflux 
during cerebral ischemia has used mice with neuronal expression of hENT1 and wild type  
littermates to compare responses to in vitro and in vivo hypoxic / ischemic conditions 
(Zhang et al., 2011). Hypoxia /  oxygen-glucose deprivation produced greater inhibition of 
excitatory neurotransmission in slices from wild type mice than from mice expressing 
hENT1. Presence of NBMPR abolished these differences, which altogether indicated that 
neuronal equilibrative NTs reduce hypoxia / ischemia-induced increase in extracellular 
adenosine concentrations (Zhang et al., 2011). This may suggest that that inhibition of 
neuronal adenosine transporters may beneficial for the treatment of cerebral ischemia. 
A recent study has revealed that hypoxia and glucose deprivation can also affect expression 
of nucleoside transporters in rat astrocytes in primary culture. Those cells expressed rENT1, 
rENT2, rCNT1 and rCNT3; rCNT2 was present at transcript level but the protein could not 
be detected (Redzic et al., 2010b). Hypoxia and glucose deprivation (60 min) was 
accompanied by an increase in adenosine and ATP concentration in culture medium and 
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caused a decrease in the expression of rENT1 in astrocytes; hypoxia and glucose deprivation 
followed by 1 h recovery period caused a decrease in the expression of rENT1 and rENT2 
and a decrease in equilibrative cellular uptake of [3H]adenosine by astrocytes (Redzic et al., 
2010b). Astrocyte cultures that were subjected to 1h hypoxia and glucose deprivation that 
was followed by 1 h recovery period were less able to take up [3H]adenosine by 
equilibrative mechanisms   than cultures from the control group.  That decrease in uptake 
ability could potentially increase ISF adenosine  during ischemia (Redzic et al., 2010b). 
6. Transport of anti-HIV drugs by human nucleoside transporters 
Since the onset of the AIDS pandemic in 1981, infection with the human immunodeficiency 
virus (HIV) infection has spread exponentially throughout the world. HIV is neuro-invasive 
(with invasion occurring early in the course of the infection), neuro-virulent (causing a 
neuropathy, myopathy, myelopathy, and dementia), but it is not especially neurotrophic 
(Manji and Miller 2004). Several drugs are now available for treatment of HIV infection, 
including the following nucleoside analogues reverse transcriptase inhibitors: zidovudine 
(1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-
tetrahydropyrimidine-2,4-dione), also known as 3′-azido-3′-deoxythymidine (trade name 
Retrovir), abacavir [4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-1- cyclopent-2-
enyl]methanol) ( trade name Ziagen),  stavudine (1-[(2R,5S)-5-(hydroxymethyl)-2,5-
dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione) also known as 2'-3'-
didehydro-2'-3'-dideoxythymidine (trade name Zerit), lamivudine (4-amino-1-[(2R,5S)-2-
(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one) also known as 2',3'-
dideoxy-3'-thiacytidine (trade names Zeffix, Heptovir or Epivir),  emitricitabine (4-amino-5-
fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one), trade 
name Emtriva, zalcitabine (4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,2-
dihydropyrimidin-2-one) also known as 2'-3'-dideoxycytidine (trade name Hivid) and 
didanosine (9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one) also 
known as 2',3'-dideoxyinosine (trade name Videx).  Potentially, all those nucleoside 
analogues could be used for the neuro-HIV treatment; however, their effect on HIV 
replication in the brain largely depends on its ability to enter the CNS and concentrations 
that they can achieve in the brain ECF and in the cytoplasm. Transport across the BBB 
largely depends on physico-chemical characteristics of a drug (polarity, lipophilicity, 
molecular weight) (for the role of lipophilicity in the BBB passage see Abbott et al., 2008 and 
Abbott et al., 2010). Based upon their measured CSF concentrations and therapeutic effects, 
these anti-HIV nucleosides are classified either as high CNS penetrating drugs (zidovudine 
and abacavir), intermediate CNS penetrating drugs (stavudine, lamivudine and 
emitricitabine) or low CNS penetrating drugs (zalcitabine and didanosine) (Letendre et al., 
2008).The first drug that was approved for AIDS was zidovudine. Intracellularly, this drug 
is phosphorylated to azidothymidine triphosphate, which then inhibits reverse transcriptase 
and thus impedes viral replication.  This drug was partially successful in controlling 
replication of HIV in the brain. NTs- mediated uptake across the BBB of zidovudine is low; 
however, because of its lipophilic nature, it passes the BBB by a simple diffusion and then 
enters the cells. Thus, it appears that distribution of zidovudine in the brain fluids largely do 
not depend on NT- mediated transport across the BBB and CPs (Thomas and Segal., 1997). 
However, in vitro studies confirmed that zidovudine, zalcitabine and didanosine are 
substrates for several nucleoside transporters (Table 2) (Baldwin et al., 2005, Yao et al., 2001).  
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RTI 
Nucleoside transporter that 
mediate transport 
Source 
Zidovudine  hENT2, hENT3, hCNT1 
Baldwin et al., 2005, Yao et 
al., 2001 
Zalcitabine hENT1-3, hCNT1, hCNT3 
Baldwin et al., 2005, Yao et 
al., 2001 
Didanosine hENT2*, hENT3, hCNT2, hCNT3 
Baldwin et al., 2005, Yao et 
al., 2001 
Table 2. Transport of nucleoside analogues reverse transcriptase inhibitors (RTIs) by human 
nucleoside transporters. *The estimated Km value for hENT2 is 2.3 mM  
Human ENT2, expressed in Xenopus oocytes, transports zidovudine, zalcitabine and 
didanosine (Yao et al., 2001). Human ENT3 (which is mainly located intracellularly) also 
transports these three nucleoside analogues, while hENT1 transports zalcitabine. hCNT1, 
which is pyrimidine nucleoside-selective, transports pyrimidine analogues zidovudine and 
zalcitabine, hCNT2, which is purine nucleoside-selective, transports purine analogue 
didanosine, while hCNT3, which is broadly selective, transports all three drugs (Smith et al., 
2004, Smith et al., 2005).  
7. Conclusion 
Over the last two decades, seven separate human nucleoside transporters have been cloned 
and  successfully produced as functional  recombinant proteins in a heterologous expression 
system (Xenopus Laevis oocytes), which enabled their functional characterization. Findings 
from these studies provided the tools that were needed to better understand nucleoside 
transport in the brain under normal physiological conditions and under various 
pathophysiological conditions (e.g. ischemia / hypoxia) as well as to understand therapeutic 
potential of these processes. Molecular structure of equlibrative nucleoside transporters has 
been elucidated, but more data on clarification of concentrative nucleoside transporters 
molecular architecture are still needed. The roles of individual nucleoside transporters in 
cells that possess multiple transporter isoforms are still not being fully elucidated, which 
also applies to their roles in the brain. An important attempt to disentanglement the 
contributions of individual nucleoside transporters was done by a genetic knock-out 
approach, which produced mENT1-null mice. Such knowledge should provide important 
data required to produce nucleoside analogues reverse transcriptase inhibitors that are 
brain-accessible. 
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